{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T11:06:48Z","timestamp":1790593608476,"version":"4.1.0"},"reference-count":22,"publisher":"Athenaeum Scientific Publishers","issue":"3","content-domain":{"domain":["athenaeumpub.com"],"crossmark-restriction":true},"short-container-title":["JOAR"],"abstract":"<jats:p>Purpose: Glucagon-Like Peptide 1 Receptor Agonists (GLP-1RAs) are antidiabetic and weight management medications that bind to GLP-1 receptors throughout the body. Growing interest in this class has led to several retrospective cohort studies reporting a decreased occurrence of glaucoma in diabetic and non-diabetic patients with the use of GLP-1RAs, suggestive of anti-inflammatory and neuroprotective effects. Here we report five real world cases evaluating the impact of GLP-1RA and dual GLP-1\/Gastric Inhibitory Polypeptide (GIP) receptor agonist use on Intraocular Pressure (IOP) measurements and subsequent disease management in glaucoma patients.\n\nObservations: Case 1 (severe pigment dispersion glaucoma OU) was started on semaglutide on two separate occasions and exhibited clinically significant declines in home IOP tonometry readings after each initiation (OD max: 20 to 18, 16 to 14; OS: 22 to 15, then 20 to 17). Case 2 (severe primary open angle glaucoma OU) was a candidate for filtration device surgery when he began taking tirzepatide, after which a decrease in home IOP tonometry readings was observed (OD: 11 to 8; OS: 21 to 14), resulting in surgery postponement. Case 3 (secondary glaucoma OD following trauma) began taking tirzepatide shortly following glaucoma drainage device implantation and experienced unexplained hypotony (IOP: 25 to 4). Case 4 (severe POAG OU) was taking semaglutide with stable IOPs until pancreatitis prompted cessation of semaglutide, whereupon an increase in IOP was subsequently observed (OD: 23 to 30; OS: 16 to 18). Case 5 (undiagnosed) is a patient na\u00efve to IOP-lowering therapy and initiation of tirzepatide correlated with an abrupt reduction in IOP observed in clinic (OU: 24 to 10).\n\nConclusion and Importance: These cases demonstrate a potential association between GLP-1\/GIP receptor agonist use and IOP lowering in patients with glaucoma and help substantiate existing literature with real world cases, thereby highlighting the need for further prospective research on this emerging topic.<\/jats:p>","DOI":"10.46889\/joar.2026.7306","type":"journal-article","created":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T10:52:42Z","timestamp":1790592762000},"page":"1-6","update-policy":"https:\/\/doi.org\/10.46889\/crossmark","source":"Crossref","is-referenced-by-count":0,"title":["Impact of Glucagon-Like Peptide 1 (GLP-1) and Gastric Inhibitory Polypeptide (GIP) Receptor Agonists on Intraocular Pressure in Glaucoma: A Case Series"],"prefix":"10.46889","volume":"7","author":[{"given":"Coy","family":"Steel","sequence":"first","affiliation":[{"name":"John A. Moran Eye Center, University of Utah, Salt Lake City, UT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Johnson","sequence":"additional","affiliation":[{"name":"John A. Moran Eye Center, University of Utah, Salt Lake City, UT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chase","family":"Paulson","sequence":"additional","affiliation":[{"name":"John A. Moran Eye Center, University of Utah, Salt Lake City, UT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesse","family":"Terrell","sequence":"additional","affiliation":[{"name":"Baylor College of Medicine, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi N","family":"Cui","sequence":"additional","affiliation":[{"name":"Scheie Eye Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Blieden","sequence":"additional","affiliation":[{"name":"Baylor College of Medicine, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Wirostko","sequence":"additional","affiliation":[{"name":"John A. Moran Eye Center, University of Utah, Salt Lake City, UT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"26248","published-online":{"date-parts":[[2026,9,27]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"844697","DOI":"10.3389\/fneur.2022.844697","article-title":"Neuroprotective mechanisms of glucagon-like peptide-1-based therapies in ischemic stroke: an update based on preclinical research","volume":"13","author":"Yang","year":"2022","unstructured":"Yang X, Qiang Q, Li N, Feng P, Wei W, H\u00f6lscher C. Neuroprotective mechanisms of glucagon-like peptide-1-based therapies in ischemic stroke: an update based on preclinical research. Front Neurol. 2022;13:844697.","journal-title":"Front Neurol"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"1156829","DOI":"10.3389\/fncel.2023.1156829","article-title":"Topical and systemic GLP-1R agonist administration both rescue retinal ganglion cells in hypertensive glaucoma","volume":"17","author":"Lawrence","year":"2023","unstructured":"Lawrence ECN, Guo M, Schwartz TD, Wu J, Lu J, Nikonov S, et al. Topical and systemic GLP-1R agonist administration both rescue retinal ganglion cells in hypertensive glaucoma. Front Cell Neurosci. 2023;17:1156829.","journal-title":"Front Cell Neurosci"},{"issue":"5","key":"ref2","doi-asserted-by":"publisher","first-page":"108271","DOI":"10.1016\/j.celrep.2020.108271","article-title":"GLP-1 receptor agonist NLY01 reduces retinal inflammation and neuron death secondary to ocular hypertension","volume":"33","author":"Sterling","year":"2020","unstructured":"Sterling JK, Adetunji MO, Guttha S, Bargoud AR, Uyhazi KE, Ross AG, et al. GLP-1 receptor agonist NLY01 reduces retinal inflammation and neuron death secondary to ocular hypertension. Cell Rep. 2020;33(5):108271.","journal-title":"Cell Rep"},{"issue":"2","key":"ref3","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1136\/bjophthalmol-2021-319232","article-title":"Glucagon-like peptide 1 receptor agonist use is associated with reduced risk for glaucoma","volume":"107","author":"Sterling","year":"2023","unstructured":"Sterling J, Hua P, Dunaief JL, Cui QN, VanderBeek BL. Glucagon-like peptide 1 receptor agonist use is associated with reduced risk for glaucoma. Br J Ophthalmol. 2023;107(2):215-20.","journal-title":"Br J Ophthalmol"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Niazi S, Gnesin F, Thein AS, Andreasen JR, Horwitz A, Mouhammad ZA, et al. Association between glucagon-like peptide-1 receptor agonists and the risk of glaucoma in individuals with type 2 diabetes. Ophthalmology. 2024;S0161642024001714.","DOI":"10.1016\/j.ophtha.2024.03.004"},{"issue":"3","key":"ref5","doi-asserted-by":"publisher","first-page":"540","DOI":"10.7150\/ijms.90273","article-title":"Prescription of glucagon-like peptide 1 agonists and risk of subsequent open-angle glaucoma in individuals with type 2 diabetes mellitus","volume":"21","author":"Chuang","year":"2024","unstructured":"Chuang CC, Wang K, Chang CK, Lee CY, Huang JY, Wu HH, et al. Prescription of glucagon-like peptide 1 agonists and risk of subsequent open-angle glaucoma in individuals with type 2 diabetes mellitus. Int J Med Sci. 2024;21(3):540-6.","journal-title":"Int J Med Sci"},{"issue":"11","key":"ref6","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1136\/bjo.2005.081307","article-title":"A new insight into the cellular regulation of aqueous outflow: how trabecular meshwork endothelial cells drive a mechanism that regulates the permeability of Schlemm's canal endothelial cells","volume":"89","author":"Alvarado","year":"2005","unstructured":"Alvarado JA. A new insight into the cellular regulation of aqueous outflow: how trabecular meshwork endothelial cells drive a mechanism that regulates the permeability of Schlemm's canal endothelial cells. Br J Ophthalmol. 2005;89(11):1500-5.","journal-title":"Br J Ophthalmol"},{"issue":"5","key":"ref7","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.ogla.2024.03.005","article-title":"Glucagon-like peptide 1 receptor agonists: a role in glaucoma","volume":"7","author":"Johnson","year":"2024","unstructured":"Johnson C, Pasquale LR, Wirostko B. Glucagon-like peptide 1 receptor agonists: a role in glaucoma? Ophthalmol Glaucoma. 2024;7(5):419-21.","journal-title":"Ophthalmol Glaucoma"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Hong AT, Lin F, Baxter S, Weinreb RN. Tirzepatide is associated with reduced risk of primary open-angle glaucoma and ocular hypertension in patients with type 2 diabetes. Am J Ophthalmol. 2025;S0002939425006531.","DOI":"10.1016\/j.ajo.2025.12.003"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Hallaj S, Halfpenny W, Chuter BG, Weinreb RN, Baxter SL, Cui QN. Association between Glucagon-Like Peptide 1 (GLP-1) receptor agonists exposure and intraocular pressure change. medRxiv. 2024.","DOI":"10.1101\/2024.05.06.24306943"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Botfield HF, Uldall MS, Westgate CSJ, Mitchell JL, Hagen SM, Gonzalez AM, et al. A glucagon-like peptide-1 receptor agonist reduces intracranial pressure in a rat model of hydrocephalus. Sci Transl Med. 2017;9(404):eaan0972.","DOI":"10.1126\/scitranslmed.aan0972"},{"issue":"5","key":"ref11","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1093\/brain\/awad003","article-title":"The effect of GLP-1RA exenatide on idiopathic intracranial hypertension: a randomized clinical trial","volume":"146","author":"Mitchell","year":"2023","unstructured":"Mitchell JL, Lyons HS, Walker JK, Yiangou A, Grech O, Alimajstorovic Z, et al. The effect of GLP-1RA exenatide on idiopathic intracranial hypertension: a randomized clinical trial. Brain. 2023;146(5):1821-30.","journal-title":"Brain"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Younes ST, Maeda KJ, Sasser J, Ryan MJ. The glucagon-like peptide 1 receptor agonist liraglutide attenuates placental ischemia-induced hypertension. Am J Physiol Heart Circ Physiol. 2020;318(1):H72-7.","DOI":"10.1152\/ajpheart.00486.2019"},{"issue":"1","key":"ref13","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s12868-016-0272-9","article-title":"The GLP-1 receptor agonists exendin-4 and liraglutide alleviate oxidative stress and cognitive and micturition deficits induced by middle cerebral artery occlusion in diabetic mice","volume":"17","author":"PC","year":"2016","unstructured":"Li PC, Liu LF, Jou MJ, Wang HK. The GLP-1 receptor agonists exendin-4 and liraglutide alleviate oxidative stress and cognitive and micturition deficits induced by middle cerebral artery occlusion in diabetic mice. BMC Neurosci. 2016;17(1):37.","journal-title":"BMC Neurosci"},{"issue":"4","key":"ref14","doi-asserted-by":"publisher","first-page":"525","DOI":"10.4093\/dmj.2025.0242","article-title":"Exploring the side effects of GLP-1 receptor agonist: to ensure its optimal positioning","volume":"49","author":"JA","year":"2025","unstructured":"Kim JA, Yoo HJ. Exploring the side effects of GLP-1 receptor agonist: to ensure its optimal positioning. Diabetes Metab J. 2025;49(4):525-41.","journal-title":"Diabetes Metab J"},{"issue":"9","key":"ref15","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1001\/jamaophthalmol.2025.2489","article-title":"Ocular adverse events with semaglutide: a systematic review and meta-analysis","volume":"143","author":"Natividade","year":"2025","unstructured":"Natividade GR, Spiazzi BF, Baumgarten MW, Bassotto C, Pereira AA, Fraga BL, et al. Ocular adverse events with semaglutide: a systematic review and meta-analysis. JAMA Ophthalmol. 2025;143(9):759-68.","journal-title":"JAMA Ophthalmol"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Coster D, Rafie A, Savion-Gaiger N, Rachmiel R, Kurtz S, Berliner S, et al. The effect of body mass index reduction on intraocular pressure in a large prospective cohort of apparently healthy individuals in Israel. PLoS One. 2023;18(5):e0285759.","DOI":"10.1371\/journal.pone.0285759"},{"issue":"5","key":"ref17","doi-asserted-by":"publisher","first-page":"794","DOI":"10.18240\/ijo.2020.05.15","article-title":"Relationship between intraocular pressure and parameters of obesity in ocular hypertension","volume":"13","author":"Ahn","year":"2020","unstructured":"Ahn MW. Relationship between intraocular pressure and parameters of obesity in ocular hypertension. Int J Ophthalmol. 2020;13(5):794-800.","journal-title":"Int J Ophthalmol"},{"issue":"2","key":"ref18","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1097\/01.ijg.0000435775.05032.87","article-title":"Correlation between intraocular pressure and body mass index in the seated and supine positions","volume":"24","author":"Geloneck","year":"2015","unstructured":"Geloneck MM, Crowell EL, Wilson EB, Synder BE, Chuang AZ, Baker LA, et al. Correlation between intraocular pressure and body mass index in the seated and supine positions. J Glaucoma. 2015;24(2):130-4.","journal-title":"J Glaucoma"},{"issue":"18","key":"ref19","doi-asserted-by":"publisher","first-page":"5883","DOI":"10.3390\/jcm12185883","article-title":"Intraocular pressure variations in postural changes: comparison between obese and non-obese controls","volume":"12","author":"De Bernardo","year":"2023","unstructured":"De Bernardo M, Pilone V, Di Paola I, Cione F, Cembalo G, Calabrese P, et al. Intraocular pressure variations in postural changes: comparison between obese and non-obese controls. J Clin Med. 2023;12(18):5883.","journal-title":"J Clin Med"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.ajo.2022.08.006","article-title":"Association between body mass index and primary open angle glaucoma in three cohorts","volume":"245","author":"Marshall","year":"2023","unstructured":"Marshall H, Berry EC, Torres SD, Mullany S, Schmidt J, Thomson D, et al. Association between body mass index and primary open angle glaucoma in three cohorts. Am J Ophthalmol. 2023;245:126-33.","journal-title":"Am J Ophthalmol"},{"issue":"8","key":"ref21","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/j.ophtha.2025.02.011","article-title":"Risk of glaucoma in patients without diabetes using a glucagon-like peptide 1 receptor agonist","volume":"132","author":"Vasu","year":"2025","unstructured":"Vasu P, Dorairaj EA, Weinreb RN, Huang AS, Dorairaj SK. Risk of glaucoma in patients without diabetes using a glucagon-like peptide 1 receptor agonist. Ophthalmology. 2025;132(8):859-68.","journal-title":"Ophthalmology"}],"container-title":["Journal of Ophthalmology and Advance Research"],"original-title":[],"link":[{"URL":"https:\/\/athenaeumpub.com\/wp-content\/uploads\/Impact-of-Glucagon-Like-Peptide-1-GLP-1-and-Gastric-Inhibitory-Polypeptide-GIP-Receptor-Agonists-on-Intraocular-Pressure-in-Glaucoma-A-Case-Series.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T10:53:27Z","timestamp":1790592807000},"score":1,"resource":{"primary":{"URL":"https:\/\/athenaeumpub.com\/impact-of-glucagon-like-peptide-1-glp-1-and-gastric-inhibitory-polypeptide-gip-receptor-agonists-on-intraocular-pressure-in-glaucoma-a-case-series\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,27]]},"references-count":22,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,9,27]]}},"URL":"https:\/\/doi.org\/10.46889\/joar.2026.7306","relation":{},"ISSN":["3050-9459"],"issn-type":[{"value":"3050-9459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,27]]}}}